Neuroactive steroid biosynthesis during pregnancy predicts future postpartum depression: a role for the 3α and/or 3β-HSD neurosteroidogenic enzymes?
- PMID: 39885361
- PMCID: PMC12032070
- DOI: 10.1038/s41386-025-02052-z
Neuroactive steroid biosynthesis during pregnancy predicts future postpartum depression: a role for the 3α and/or 3β-HSD neurosteroidogenic enzymes?
Erratum in
-
Correction: Neuroactive steroid biosynthesis during pregnancy predicts future postpartum depression: a role for the 3α and/or 3β-HSD neurosteroidogenic enzymes?Neuropsychopharmacology. 2025 May;50(6):1021. doi: 10.1038/s41386-025-02109-z. Neuropsychopharmacology. 2025. PMID: 40247014 Free PMC article. No abstract available.
Abstract
Postpartum depression (PPD) affects ~10-15% of childbearing individuals, with deleterious consequences for two generations. Recent research has explored the biological mechanisms of PPD, particularly neuroactive steroids (NAS). We sought here to investigate associations between NAS levels and ratios during pregnancy and the subsequent development of depressive symptoms with postpartum onset. NAS levels and psychological scales were measured in individuals with and without mood disorders at up to eight visits across pregnancy and postpartum. Generalized linear mixed-effects regression models were used to assess relationships in euthymic pregnant individuals between each of the NAS biomarkers and ratios and subsequent PPD. Participants with a one-unit increase in the log isoallopregnanolone/pregnanolone ratio at the third trimester (T3) had higher odds (OR = 1.64, 95% CI: 1.13-2.37, FDR adjusted p = 0.038, C-index = 0.82), and those with a one-unit increase in the log pregnanolone/progesterone ratio at T3 had lower odds (OR = 0.64, 95% CI: 0.47-0.88, FDR adjusted p = 0.036, C-index = 0.82) of developing PPD; those with a one-unit increase in the log progesterone level at T3 had higher odds of developing PPD (OR = 4.00, 95% CI: 1.54-10.37, FDR adjusted p = 0.035, C-index = 0.80). We found key differences in the progesterone metabolic pathway at the third trimester, indicating likely decreased activity/expression of the 3α-HSD enzyme and/or increased activity/expression of 3β-HSD.
© 2025. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.
Conflict of interest statement
Competing interests: JLP holds the rights to two patents: “DNA Methylation Biomarkers of PPD Risk” and “Epigenetic Biomarkers Predictive of Premenstrual Dysphoric Disorder, Perimenopausal Depression and SSRI Response.” JLP owns founders’ stock in Dionysus Health. She has served as a consultant to the following companies: Biogen, SAGE Therapeutics, Merck, Brii Biologics, Pure Tech, Flo Health. JLP also receives research support from Janssen and Myriad. GP served as a paid consultant to PureTech Health (Boston, MA, USA), GABA Therapeutics, and NeuroTrauma Sciences (Alpharetta, GA, USA). He has two patent applications, one on N-palmitoylethanolamine (PEA) and peroxisome proliferator-activated receptor alpha (PPAR-α) agonists US20180369171A1 allowed on May 16, 2023, and one on allopregnanolone analogs US11266663B2 allowed on March 8, 2022, in the treatment of neuropsychiatric disorders. The other authors report no relevant financial interests.
References
-
- Pregnancy-Related Deaths: Data from Maternal Mortality Review Committees in 36 US States, 2017–2019 CDC. 2022. https://www.cdc.gov/reproductivehealth/maternal-mortality/erase-mm/data-.... Accessed 21 Apr 2024.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
